Medicare Enrolled

Dr. Asif Cochinwala, M.D.

Rheumatology · Cypress, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
21212 NORTHWEST FWY STE 375, Cypress, TX 77429
8322370400
In practice since 2005 (20 years)
NPI: 1245212521 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Cochinwala from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Cochinwala? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Cochinwala

Dr. Asif Cochinwala is a rheumatology in Cypress, TX, with 20 years in practice. Based on federal Medicare data, Dr. Cochinwala performed 24,555 Medicare services across 1,595 unique beneficiaries.

Between the years covered by Open Payments, Dr. Cochinwala received a total of $8,097 from 32 pharmaceutical and/or device companies across 313 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Cochinwala is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice▲ Top 31% volume in TX$ $8,097 industry payments

Medicare Practice Summary

Medicare Utilization ↗
24,555
Medicare services
Top 31% in TX for rheumatology
1,595
Unique beneficiaries
$21
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,228 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Golimumab infusion (Simponi Aria)10,301$10$70
Infliximab infusion (Remicade)5,620$26$230
Denosumab injection (Prolia/Xgeva)4,740$18$35
Office visit, established patient (20-29 min)746$68$105
Blood draw (venipuncture)597$8$25
Office visit, established patient (30-39 min)321$89$165
Measurement of antibody for assessment of autoimmune disorder, any method308$17$94
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle263$60$300
Administration of chemotherapy into vein, 1 hour or less250$104$375
Measurement of dna antibody, native or double stranded146$13$94
Analysis of substance using immunoassay technique, multiple step method126$11$70
Beta 2 glycoprotein 1 antibody (autoantibody) measurement114$24$150
Cardiolipin antibody (tissue antibody) measurement114$24$167
Administration of chemotherapy into vein, each additional hour103$23$250
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less85$22$250
Injection, diphenhydramine hcl, up to 50 mg84$1$35
Bone density scan (DEXA)81$39$400
Chronic care management, first 20 min/month80$51$100
New patient office visit (45-59 min)78$125$350
Screening test for autoimmune disorder71$12$69
Rheumatoid factor level63$5$43
Steroid injection (triamcinolone)54$1$14
Measurement of antibody for rheumatoid arthritis assessment45$12$35
Measurement of dna antibody, single stranded44$12$50
X-ray of hand, minimum of 3 views30$22$125
Chest X-ray, 2 views28$18$125
Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service)24$51$90
New patient office visit (30-44 min)20$84$200
Chronic care management, additional 20 min/month19$39$100
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
65.2% high complexity
22.4% medium
12.4% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$8,097
Total received (2018-2024)
Avg $1,157/year across 7 years
Top 38% in TX for rheumatology
32
Companies
313
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,769 (71.2%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,899 (23.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$429 (5.3%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,167
2023
$937
2022
$782
2021
$384
2020
$334
2019
$2,882
2018
$1,611

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$2,069
Amgen Inc.
$1,691
UCB, Inc.
$673
Novartis Pharmaceuticals Corporation
$624
ABBVIE INC.
$564
Genentech USA, Inc.
$256
AstraZeneca Pharmaceuticals LP
$238
GlaxoSmithKline, LLC.
$230
Radius Health, Inc.
$219
Lilly USA, LLC
$178
AbbVie, Inc.
$163
Celgene Corporation
$144
AbbVie Inc.
$134
Sandoz Inc.
$114
Boehringer Ingelheim Pharmaceuticals, Inc.
$104
E.R. Squibb & Sons, L.L.C.
$97
Octapharma USA, Inc.
$66
Horizon Therapeutics plc
$64
Horizon Pharma plc
$63
PFIZER INC.
$60
Merck Sharp & Dohme Corporation
$57
Alvogen Inc
$49
Aurinia Pharma U.S., Inc.
$41
West-Ward Pharmaceuticals
$37
Fresenius Kabi USA, LLC
$28
Biocon Biologics Inc
$21
Mylan Institutional Inc.
$21
GENZYME CORPORATION
$20
Fidia Pharma USA Inc.
$20
SANOFI-AVENTIS U.S. LLC
$19
Hikma Pharmaceuticals USA
$16
Bioventus LLC
$16
Top 3 companies account for 54.8% of total payments
Associated products mentioned in payments ›
AMJEVITA · Actemra · BENLYSTA · Bimzelx · COSENTYX · CYLTEZO · Cimzia · DUEXIS · EVENITY · Enbrel · Exogen · FORTEO · HUMIRA · HYMOVIS · HYRIMOZ · Hulio · Humira · IDACIO · INFLECTRA · KEVZARA · KRYSTEXXA · LUPKYNIS · Mitigare · OCREVUS · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OFEV · ORENCIA · Otezla · RAYOS · REMICADE · RENFLEXIS · RINVOQ · Rinvoq · Rituxan · SAPHNELO · SIMPONI ARIA · SKYRIZI · STELARA · TALTZ · TAVNEOS · TERIPARATIDE · TREMFYA · Tymlos · XELJANZ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (71%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $33 per 100 Medicare services performed
Looking for a rheumatology in Cypress?
Compare rheumatologys in the Cypress area by procedure volume, costs, and industry payment transparency.
Browse rheumatologys nearby

Geographic Context

Rheumatologys within 10 mi
49
Per 100K population
1.0
County median income
$73,104
Nearest hospital
LONE STAR BEHAVIORAL HEALTH CYPRESS
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Cochinwala is a mixed practice specialist, with moderate Medicare volume, and low-engagement industry engagement, with 20 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Cochinwala experienced with golimumab infusion (simponi aria)?
Based on Medicare claims data, Dr. Cochinwala performed 10,301 golimumab infusion (simponi aria) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Cochinwala receive payments from pharmaceutical companies?
Yes. Dr. Cochinwala received a total of $8,097 from 32 companies across 313 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Cochinwala's costs compare to other rheumatologys in Cypress?
Dr. Cochinwala's average Medicare payment per service is $21. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Cochinwala) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →